JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
Letrozole (also referred to as Femara) is a nonsteroidal selective aromatase inhibitor previously well characterized in the biochemical and molecular scientific databases. It is said to act selectively on the aromatase enzyme, which is responsible for converting androgens into estrogens in estrogen synthesis. Molecular selectivity has been reported for this compound with respect to aromatase activity and demonstrated no direct effects on corticosteroid synthetic pathways.
Letrozole was originally developed by the pharmaceutical company Novartis during the 1980s and has since been widely examined in academic and laboratory research contexts. Ongoing investigations reference its role as a research compound for studying estrogen-dependent signaling mechanisms and hormone-regulated cellular processes. At Element CRP, access to liquid letrozole is limited exclusively to educational and research institutions, and the material is supplied strictly for laboratory research purposes only.
From Pubchem
IUPAC Name:4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrileSynonyms: 112809-51-5, FemaraMolecular Formula: C17H11N5Molecular Weight: 285.30 g/molCAS Number: 112809-51-5PubChem CID: 3902
Letrozole is also been explored as a substance that binds to the aromatase enzyme in biochemical research. Aromatase is the enzyme that mediates the transformation of androgenic precursors to estrogen, and thus it appears to be a major regulator in biosynthesis sequence of estrogens. Regulation of aromatase activity modifies downstream estrogen receptor rollercoaster in estrogen-dependent cellular systems. Long-term E2 signaling pathways are well characterized because of their involvement in cell proliferation, differentiation and survival.
Research literature describes comparative analyses of aromatase inhibitors to examine differences in enzyme binding characteristics, selectivity profiles, and downstream molecular signaling behavior. Sequential and intermittent modulation strategies are explored in experimental models to understand adaptive cellular responses and signaling plasticity associated with sustained aromatase inhibition. These investigations focus on resistance-associated signaling adaptations, feedback regulation, and pathway reactivation observed in estrogen-responsive cellular environments.
Letrozole is studied in endocrine research as a controller of estrogen synthesis by blocking the action of aromatase, and thereby changing feedback signaling junctions at the level of biochemistry with the hypothalamic–pituitary–gonadal axis. The suppression of estrogenic signaling is related to alterations in patterns of gonadotropin-releasing, including those linked with follicle-stimulating hormone. Aromatase blockade might also influence the intra-tissue androgens concentrations which are investigated for their capacity to modulate follicular microenvironment as well as growth factor responsiveness.
Mechanistic studies addressing the inter-relationship between androgen to estrogen ratios and insulin-like growth factor signalling pathways in models of follicular development and steroidogenic regulation are presented. These studies focus more on molecular cross talk between cells, regulation of receptor sensitivity and intracellular signaling than functional or clinical end points.
In molecular studies, Estrogen receptor signaling has been associated with the regulation of the PI 3-kinase/AKT/ mTOR pathway, which is implicated in growth, metabolism and survival of normal cells. This pathway is commonly studied in estrogen driven tissue settings when uncoupled. Aromatase inhibition is investigated for its indirect effects on estrogen receptor–mediated transcriptional activity, which may be similar to PI3K/AKT/mTOR pathway modulation.
Research frameworks evaluate the combined modulation of estrogen synthesis pathways and intracellular kinase signaling networks to understand synergistic or compensatory molecular responses. These studies focus on pathway crosstalk, feedback inhibition, and signaling convergence rather than therapeutic response or outcome-based interpretation.
Letrozole has been used in research as a selective aromatase inhibitor and is designed to be used as a biochemical tool for the direct obstruction of estrogen biosynthesis, receptor-mediated responses, and hormone-dependent tumor cell. On-going studies elucidate its crosstalk with metabolic signaling network as well endocrine feedback loop systems and enzyme regulation axes in various experimental models. Active areas of investigation include estrogen-dependent hepatic signaling, trophoblastic cell behavior and post-intervention hormonal regulatory pathways.
At Element CRP, Letrozole for sale is supplied strictly for laboratory research and educational use. Availability is limited to qualified research institutions, and the compound is not intended for human or animal use, ingestion, or application outside controlled experimental settings. Only buy Letrozole if you are a qualified researcher.
Letrozole is a small-molecule non-steroidal aromatase inhibitor with a triazole-containing structure that delivers high-affinity competitive inhibition at the cytochrome P450 19A1 (CYP19A1) catalytic site. Its solution stability supports consistent enzyme kinetics characterisation across in vitro pharmacology research applications.
Cell-based research with Letrozole examines CYP19A1 (aromatase) enzyme inhibition with downstream effects on estrogen biosynthesis pathway activity in granulosa cell models and aromatase-expressing cell lines. Standard readouts include enzyme activity assays measuring estrogen production from androgen substrates and IC50 determination across diverse cell line backgrounds.
Element CRP supplies this product at 3.5mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
